|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | R-CHOP,followed by high dose therapy and autologous stem cell rescue(HDT/ASCR),and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma:a comparative effectiveness analysis from the National Comprehensive Cance Network(NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project显示文摘 | LaCase A Vandergrift JL Rodriguez MA | 2009 | Blood(ASH Annual Meeting Abstracts)2009，114，： | 1 |
| 2 | Pomalidomide plus low-dose Dexamethasone in relapsed or refractory multiple myeloma (RRMM) with deletion (del)17p and/or translocation t(4;14) 显示文摘 | Leleu X Karlin L Macro M | 2013 | Blood (ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 3 | Expression of truncated protein tyrosine phosphatase, receptor type, O (PTPROt) influences multiple myeloma sensitivity to bortezomib through akt signaling, and is a favorable clinical prognostic factor显示文摘 | Wang H Baladandayuthapani V Wang Z | 2013 | Blood (ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 4 | Preliminary report ofmulticenter prospective phase D study of DA-EPOCH-R inmycrearranged aggressive B-cell lymphoma 显示文摘 | Dunleavy K Fanale M Lacasce A | 2014 | ASH AnnualMeeting2014，，： | 1 |
| 5 | Municipal Solid Waste In cinerator Residue Recycling by Thermal Processes 显示文摘 | Shin-ichi Sakai Masakatsu Hiralka | 2000 | Ash Management2000，20，： | 1 |
| 6 | Mean Platelet Volume as a Risk Factor for Deep Vein Thrombosis ~In An Ethnically Diverse Population显示文摘 | Bennett SA Roberts LN Rogers R | 2010 | Blood ( ASH Annual Meeting Abstracts )2010，116，： | 1 |
| 7 | Clinical safety and activity in a phase 1 study of CAL-101,an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110,in patients with relapsed or refractory non-Hodgkin lymphoma显示文摘 | Kahl B Byrd JC Flinn IW | 2010 | Blood (ASH Annual Meeting Abstracts)2010，116，： | 1 |
| 8 | Clinical profile of single-agent modified-release oprozomib tablets in patienls ( Pls ) with hematologic malignancies: 显示文摘 | Ghobrial ]M | 2013 | Blood (ASH annual meeting Abstracts )2013，123，： | 1 |
| 9 | Long-term safety and effi- cacy of oral eltrombopag for the treatment of subjects with idiopath- ic thrombocytopenie purpura(ITP) :preliminary data from the EX- TEND study 显示文摘 | Russel J B Cheng G Kovaleva L | 2007 | Blood ( ASH Annual Mecting Abstracts)2007，110，11： | 1 |
| 10 | Co-existent hyperdiploidy does not abrogate the poor prognosis associated with adverse cytogenetics in myeloma 显示文摘 | Pawlyn C Melchor L Boyle EM ct at | 2013 | Blood(ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 11 | RNA-sequencing of paired pre- treatment and relapse samples reveals differentially expressed genes associated with lenalidomide t~sistanee in multiple myeloma显示文摘 | Neri P Gratton K Slaby LR | 2013 | Blood (ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 12 | A Phase lb dose-escalation study of spfit-dose oprozomih ( ONX0912 ) in patients with hematologic malignancies 显示文摘 | Savona MR | 2012 | Blood ( ASH annual meeting Abstracts )2012，122，： | 1 |
| 13 | System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myelo- ma (MM)显示文摘 | Ailawadhi S Sher S | 2008 | Blood (ASH Annual Meeting Abstracts)2008，112，： | 1 |
| 14 | Cyclophuspharnide, adriamycin, vincristine and prednisone plus rituximab ( CHOP-R ) in tludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with au- toimmune cytopenia (AIC) or Richter 's transformation (RT) : final analysis of a phase II study of the German CLI~ Study Gruup 显示文摘 | Jenke P Eichhorst B Busch R | 2011 | Blood (ASH annual meeting Abstracts)2011，，： | 1 |
| 15 | Velcade (V)- Thalidomide(T)-Dexamethasone(D)for Advanced and Refractory Multiple Myeloma (MM) : Long-Term Follow-Up of Phase Ⅰ-Ⅱ Trail UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T 显示文摘 | ZANGARI M BARLIGIE B BURNS M | 2005 | Blood (ASH Annual Meeting Abstracts)2005，106，： | 1 |
| 16 | Codon 72 polymorphism of TP53 gene is a novel prognostic marker for thalidomide therapy in multiple myeloma显示文摘 | Hattori Y Ikeda Y Suzuki Y | 2013 | Blood(ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 17 | Inflammasome and autophagy activation in symptomatic multiple myeloma could predict response to thalidomide-based chemotherapy显示文摘 | Pericole FV Duarte ASS Lazarini M | 2013 | Blood (ASH Annual Meeting Abstracts)2013，122，： | 1 |
| 18 | Clinical profile of single- agent oprozomib in patients with multiple myeloma (MM): Updated results frum a muhicenter, open-Label, dose escalation phase lh / 2 study 显示文摘 | Ravi Vij MBBS Savona M Siege DS et at | 2014 | Bl x d ( ASH annual meeting Abstracts )2014，124，21： | 1 |
| 19 | The impact of Thlfl'h2 re- sponse variations on risk of developing childhood leukaemia: a pilot study 显示文摘 | Zara MJ David GC David CJ | 2005 | Blood (ASH Annual Meeting Abstracts)2005，10，6： | 1 |
| 20 | A model system for visualization of whole body SDF-1 expression during hematopoietic cell transplant 显示文摘 | Lund T Glass T Tolar J | 2009 | Blood (ASH Annual Meeting Abstracts)2009，114，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员